AttendMe Owl Logo
AttendMe
Evidence Evolution
Plastic SurgeryPlastic Surgery

How This Evidence Evolved

Fat Grafting in Reconstructive Surgery

Coleman structural fat grafting and the oncologic safety debate

30.2

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Fat grafting long carried the stigma of variable results, and many surgeons who first reported failure later reported success after changing how they harvested, refined and placed the fat. In his structural fat grafting work, Sydney Coleman argued that grafted fat has many attributes of an ideal filler but that its results, like those of any procedure, depend on technique. Surgeons who refined their techniques reported long-term survival and volume replacement with grafted fat, and transplanted fat also improved the tissues into which it was placed.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Fat grafting to the breast raised oncologic safety concerns. Matched-cohort studies then tested recurrence: Petit et al. (321 lipofilling patients, 2 matched controls each) found comparable local event rates (HR 1.11, 95% CI 0.47-2.64), though risk was higher in 37 patients with intraepithelial neoplasia, and Kronowitz 2016 found 5-year locoregional recurrence of 1.6% with lipofilling vs 4.1% without.
Extension

Follow-up studies, subgroup analyses, and real-world validation

The Coleman Technique report described uncertainty about adipose-derived stem cells in graft survival. RESTORE-2 tested regenerative-cell-enriched fat grafting. RESTORE-2, a single-arm prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafts for breast-conserving therapy defects (67 patients treated), reported patient satisfaction in 50 of 67 at 12 months, improved breast contour on blinded MRI in 54 of 65, no serious injection-procedure-related adverse events, no local recurrences and injection-site cysts in 10. As a single-arm trial, it did not compare enriched with standard fat grafts. The Coleman Technique report also noted that surgeons had seen improvement in aging skin, scars, radiation damage, chronic ulceration and breast capsular contracture.
Now

Current standard of care and ongoing research directions

Coleman described technique-dependent volume replacement and observed changes in surrounding tissues, while stating that the role of adipose-derived stem cells in graft survival remained unclear. RESTORE-2 studied ADRC-enriched grafting in a single-arm cohort after breast-conserving therapy: 50 of 67 treated patients were satisfied through 12 months, and blinded MRI found contour improvement in 54 of 65. No serious injection-procedure-related events were reported, but ten patients developed injection-site cysts. These findings do not compare enrichment with standard grafting. What are the longer-term oncologic outcomes and the comparative effects of processing methods, platelet-rich plasma or cell-enrichment protocols?

Landmark Trials in This Story

Petit 20122012

Locoregional recurrence risk after lipofilling in breast cancer patients.

Local events at median 56 months from primary surgery (26 months from lipofilling): lipofilling 8 vs control 19 patients (HR 1.11, 95% CI 0.47-2.64; p=0.792); higher risk in the intraepithelial neoplasia subgroup (37 cases)

Ann OncolMatched cohort study: 321 consecutive breast cancer patients (surgery 1997-2008) with reconstructive lipofilling, each matched to 2 patients without lipofilling
ASPS Fat Graft Task Force2009

Current applications and safety of autologous fat grafts: a report of the ASPS fat graft task force.

Practice recommendations on 5 questions: applications (mainly breast), risks and complications, effect of technique, patient selection, and research advances (recommendation text not in the abstract)

Plast Reconstr SurgTask force literature review with critical appraisal and evidence-based practice recommendations (ASPS task force formed in 2007)
RESTORE-22012

Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE-2 trial.

Satisfaction through 12 months: patients 50/67, investigators 57/67; blinded MRI breast contour improved in 54/65; no serious injection-procedure-related adverse events, no local recurrences, injection-site cysts in 10 (single arm, no comparator)

Eur J Surg OncolSingle-arm, prospective, multicentre trial of ADRC-enriched fat grafting for breast-conserving therapy defects <=150 mL (71 enrolled, 67 treated)N=71
Kronowitz 20162016

Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study.

Locoregional recurrence at 5 years (Kaplan-Meier): lipofilling 1.6% vs control 4.1%; crude 1.3% (9/719) vs 2.4% (16/670); systemic recurrence 2.4% vs 3.6% (p=0.514)

Plast Reconstr SurgMatched controlled study: 719 breasts with mastectomy for cancer and lipofilling vs 670 matched breasts reconstructed without lipofilling (1981-2014); mean follow-up 60 vs 44 months

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Is fat grafting to the breast safe after breast cancer treatment?+
Two matched observational studies reported recurrence outcomes: Petit et al. (321 patients; HR 1.11, 95% CI 0.47-2.64) and Kronowitz et al. (5-year locoregional recurrence 1.6% with lipofilling vs 4.1% without). These comparisons do not establish absence of increased risk. Petit et al. found higher risk in intraepithelial neoplasia (37 cases) and called for longer follow-up.
How much fat survives after grafting?+
Results depend on technique. Coleman reported that surgeons who changed how they harvest, refine and place fat obtained long-term survival and volume replacement with grafted fat. In RESTORE-2, blinded MRI showed improved breast contour in 54 of 65 patients after ADRC-enriched grafting.
What is cell-assisted lipotransfer and is it better than standard fat grafting?+
RESTORE-2 used an automated system to isolate adipose-derived regenerative cells from harvested fat and prepare an enriched fat graft for immediate implantation. This is not evidence for a pure stem-cell preparation. The single-arm study treated 67 patients after breast-conserving therapy: no local recurrences or serious procedure-related adverse events were reported, but ten patients had injection-site cysts. It had no control group.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026